PD-1

[Coherus BioSciences, Inc.] Coherus BioSciences, Inc. announced that the FDA has granted Orphan Drug Designation for toripalimab, a PD-1 inhibitor, for the treatment of small cell lung cancer.

[Cancer Discovery] Scientists found that a combination of interferon alpha and anti-PD-1-based immunotherapy resulted in enhanced antitumor activity in unresectable hepatocellular carcinoma patients.

[Proceedings of the National Academy of Sciences of the United States of America] Using a range of mouse genetic models, researchers uncovered a critical tolerogenic axis between the autoimmune regulator, AIRE, and the immune checkpoint molecule, PD-1.

[Nature Communications] Investigators comprehensively analyzed peripheral blood and/or synovial fluid samples from 20 patients with immune-related adverse events, including arthritis, and unmasked a prominent Th1-CD8+ T cell axis in both blood and inflamed joints.

[IO Biotech] IO Biotech, a clinical-stage biopharmaceutical company developing immune-modulating cancer therapies based on its T-win® technology platform, announced that it has dosed the first patient, in metastatic non-small cell lung cancer, in its Phase II IOB-022 / KN-D38 trial.

[Proceedings of the National Academy of Sciences of the United States of America] Using a range of mouse genetic models, researchers uncovered a critical tolerogenic axis between the autoimmune regulator, AIRE, and the immune checkpoint molecule, PD-1.